Prosecution Insights
Last updated: November 20, 2026
Application No. 18/397,530

MULTI-CHANNEL DRUG DETECTION DEVICE AND METHOD

Non-Final OA §102§103
Filed
Dec 27, 2023
Priority
Dec 29, 2022 — RE 10-2022-0189892
Examiner
MUI, CHRISTINE T
Art Unit
1797
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Korea Electronics Technology Institute
OA Round
1 (Non-Final)
78%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
1097 granted / 1399 resolved
+13.4% vs TC avg
Strong +20% interview lift
Without
With
+19.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
64 currently pending
Career history
1482
Total Applications
across all art units

Statute-Specific Performance

§101
2.8%
-37.2% vs TC avg
§103
47.9%
+7.9% vs TC avg
§102
23.0%
-17.0% vs TC avg
§112
20.3%
-19.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1399 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Claims 7-13 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected method, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 10 SEPTEMBER 2026. Applicant’s election without traverse of Group I: Claims 1-6 in the reply filed on 10 SEPTEMBER 2026 is acknowledged. Status of Claims Applicant has elected Group I: Claims 1-6 on 10 SEPTEMBER 2026. Current pending claims are Claims 1-6 and are considered on the merits below. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statement (IDS) submitted on 27 DECEMBER 2023 was filed. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. The information disclosure statement (IDS) submitted on 17 JUNE 2025 was filed. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Drawings The drawings are objected to as failing to comply with 37 CFR 1.84(p)(5) because they include the following reference character(s) not mentioned in the description: Figure 3, character S32 and S70. Corrected drawing sheets in compliance with 37 CFR 1.121(d), or amendment to the specification to add the reference character(s) in the description in compliance with 37 CFR 1.121(b) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Interpretation The following is a quotation of 35 U.S.C. 112(f): (f) Element in Claim for a Combination. – An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The following is a quotation of pre-AIA 35 U.S.C. 112, sixth paragraph: An element in a claim for a combination may be expressed as a means or step for performing a specified function without the recital of structure, material, or acts in support thereof, and such claim shall be construed to cover the corresponding structure, material, or acts described in the specification and equivalents thereof. The claims in this application are given their broadest reasonable interpretation using the plain meaning of the claim language in light of the specification as it would be understood by one of ordinary skill in the art. The broadest reasonable interpretation of a claim element (also commonly referred to as a claim limitation) is limited by the description in the specification when 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is invoked. As explained in MPEP § 2181, subsection I, claim limitations that meet the following three-prong test will be interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph: (A) the claim limitation uses the term “means” or “step” or a term used as a substitute for “means” that is a generic placeholder (also called a nonce term or a non-structural term having no specific structural meaning) for performing the claimed function; (B) the term “means” or “step” or the generic placeholder is modified by functional language, typically, but not always linked by the transition word “for” (e.g., “means for”) or another linking word or phrase, such as “configured to” or “so that”; and (C) the term “means” or “step” or the generic placeholder is not modified by sufficient structure, material, or acts for performing the claimed function. Use of the word “means” (or “step”) in a claim with functional language creates a rebuttable presumption that the claim limitation is to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites sufficient structure, material, or acts to entirely perform the recited function. Absence of the word “means” (or “step”) in a claim creates a rebuttable presumption that the claim limitation is not to be treated in accordance with 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. The presumption that the claim limitation is not interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, is rebutted when the claim limitation recites function without reciting sufficient structure, material or acts to entirely perform the recited function. Claim limitations in this application that use the word “means” (or “step”) are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. Conversely, claim limitations in this application that do not use the word “means” (or “step”) are not being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, except as otherwise indicated in an Office action. This application includes one or more claim limitations that do not use the word “means,” but are nonetheless being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, because the claim limitation(s) uses a generic placeholder that is coupled with functional language without reciting sufficient structure to perform the recited function and the generic placeholder is not preceded by a structural modifier. Such claim limitation(s) is/are: A “switching unit … configured to select one of the plurality of sensor” in claim 4. A “unit” does not connote any particular structure. The specification describes the ‘switching unit’ to be “a first input terminal 221a connected to the oscillator 240, a plurality of first output terminals 222a connected to the pins of the second connector 210 each connected to one end of the sensor 120, a second output terminal 222b connected to the receiver 250, and a plurality of second input terminals 221b connected to the pins of the second connector 210 each connected to the other end of the sensor 120.” ; in [0051]. Because this/these claim limitation(s) is/are being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, it/they is/are being interpreted to cover the corresponding structure described in the specification as performing the claimed function, and equivalents thereof. If applicant does not intend to have this/these limitation(s) interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph, applicant may: (1) amend the claim limitation(s) to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph (e.g., by reciting sufficient structure to perform the claimed function); or (2) present a sufficient showing that the claim limitation(s) recite(s) sufficient structure to perform the claimed function so as to avoid it/them being interpreted under 35 U.S.C. 112(f) or pre-AIA 35 U.S.C. 112, sixth paragraph. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1 and 5-6 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by NOZAKI, US Patent 7,036,375 B2. Applicant’s invention is directed towards a device. Regarding Claim 1, the reference NOZAKI discloses a multi-channel drug detection device, Figure 15, sensor, Column 15 line 3-23, comprising: a sensor board comprising a plurality of sensors into each of which a sample is inserted, Figure 15, block 26 with resonators X1to X4, Column 15 line 3-23; and a main body connected to the sensor board, Figure 15, substrate 25, Column 15 line -23, the main body configured to analyze an electrical signal provided from the sensor board and determine whether a target material is preset in the sample, Figure 1, 2 and 15, connecting terminals TA and TB e connected to two measuring terminals of an admittance measuring unit 2, Figure 2, Column 5 line 34-48. Additional Disclosures Included are: Claim 5: wherein the multi-channel drug detection device according to claim 1, wherein: the main body comprises: an oscillator configured to provide electrical signals of predetermined frequencies to the plurality of sensors of the sensor board, Figure 7, voltage controlled oscillator 11, Column 6 line 60 -65; a receiver configured to generate a signal representing a magnitude of an electrical signal obtained from the sensor, Figure 7, phase detectors PD1, PD2, Column 7 line 6 line 60-65; and a processor configured to control the oscillator so that the predetermined frequencies are generated and to determine whether a target material is present in the sample based on a signal obtained from the receiver, the processor configured to determine an amount of the target material with reference to a reference table to correct a change in a resonance frequency of the sensors according to temperature and humidity, Figure 2, processor 3, Figure 11, Column 11 line 47-Column 12 line 29. ; and Claim 6: wherein the multi-channel drug detection device according to claim 5, wherein the processor is configured to determine a weight according to a speed of the resonance frequency that changes immediately after the sample is inserted into the sensor board, Column 3 line 52-63, Column 20 line 16-21, 48-Column 21 line 5, and predict a frequency range within which the resonance frequency is to be searched for using a Kalman filter using the weight. Claims 1 and 2 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by KR 10-1655302 B1 to LEE, submitted on the Information Disclosure Statement on 27 DECEMBER 2026, Applicant’s invention is directed to a device. Regarding Claim 1 the LEE reference discloses a multi-channel drug detection device, abstract, comprising: a sensor board comprising a plurality of sensors into each of which a sample is inserted, Figure 1-4, piezoelectric substrate 200 with sensors 310/320/300; and a main body connected to the sensor board, Figure 1, base substrate 110, the main body configured to analyze an electrical signal provided from the sensor board and determine whether a target material is preset in the sample, The driving principle of the second or third unit sensor 320 or 330 is exemplified. An electrical signal is transmitted through the IDT electrode 301 to generate a mechanical wave. This wave is changed by a physical, chemical, and electrical reaction by binding the receptor and the target substance or the binding substance contained in the reaction film 700 on the surface of the SAW sensor. Additional Disclosure Included is: Claim 2 : wherein the multi-channel drug detection device according to claim 1, wherein: the sensor board comprises a first connector electrically connected to the plurality of sensors, the main body comprises a second connector connected to the first connector, and the first connector and the second connector are pin array-type connectors, Figure 1, electrodes 400. Claims 1, 2 and 5 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by BARKER, US Publication No. 2008/0241933 A1. Applicant’s invention is directed towards a device. Regarding Claim 1, the BARKER reference discloses a multi-channel drug detection device, Figure 1, comprising: a sensor board comprising a plurality of sensors into each of which a sample is inserted, Figure 1 and 2, bottom unit 41, [0034]; and a main body connected to the sensor board, Figure 1, SAW printed circuit board 49, [0033-0035], the main body configured to analyze an electrical signal provided from the sensor board and determine whether a target material is preset in the sample, [0033, 0035, 0036, 0039, 0045]. Additional Disclosures Included are: Claim 2; wherein the multi-channel drug detection device according to claim 1, wherein: the sensor board comprises a first connector electrically connected to the plurality of sensors, [0038], Figure 2, device 29 has electrical connections 31, the main body comprises a second connector connected to the first connector, and the first connector and the second connector are pin array-type connector, Figure 1 and 2, [0035], SAW PCB 49 contains pins. ; and Claim 5: wherein the multi-channel drug detection device according to claim 1, wherein: the main body comprises: an oscillator configured to provide electrical signals of predetermined frequencies to the plurality of sensors of the sensor board, Figure 7, voltage controlled oscillator 11, Column 6 line 60 -65; a receiver configured to generate a signal representing a magnitude of an electrical signal obtained from the sensor, Figure 7, phase detectors PD1, PD2, Column 7 line 6 line 60-65; and a processor configured to control the oscillator so that the predetermined frequencies are generated and to determine whether a target material is present in the sample based on a signal obtained from the receiver, the processor configured to determine an amount of the target material with reference to a reference table to correct a change in a resonance frequency of the sensors according to temperature and humidity, Figure 2, processor 3, Figure 11, Column 11 line 47-Column 12 line 29. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 3 and 4 are rejected under 35 U.S.C. 103 as being unpatentable over KR 10-1655302 B1 to LEE, submitted on the Information Disclosure Statement on 27 DECEMBER 2026 or BARKER, US Publication No. 2008/0241933 A1, and further in view of GIRI, US Publication No. 2018/021777 A1. Regarding Claim 3, the reference LEE or BARKER disclose the claimed invention, but is silent in regards to further comprising a calibration board. GIRI discloses a multi-channel drug detection device, Figure 3, comprising: a sensor board comprising a sensor into which a sample is inserted, Figure 7, [0082], cassette 1010 receives sample; and a main body connected to the sensor board, the main body configured to analyze an electrical signal provided from the sensor board and determine whether a target material is preset in the sample, Figure 7, cassette interface 1200, [0082, 0083], wherein: the sensor board comprises a first connector electrically connected to the sensor, Figure 7, electrical connectors 1016 comprises pins, [0083], the main body comprises a second connector connected to the first connector, and the first connector and the second connector are pin array-type connector, Figure 7 electrical connector 1206, which comprises prongs, [0126, 0129]; further comprising a calibration board which comprises a third connector connected to the second connector and coupled to the main body to perform calibration before connecting a sensor board having a different operating frequency, Figure 7, cassette interface 1200 is reusable with multiple exchanged cassettes 1010 that has electrical connectors 1016 and cassette board 1012, of which one is interpreted to be a calibration cassette, [0125]. Additional Disclosure Included is: Claim 4: wherein the multi-channel drug detection device according to claim 3, wherein: the main body comprises: a switching unit connected to the second connector and configured to select one of the plurality of sensors of the sensor board, Figure 7, printed circuit board 1210, [0131]; and a matching circuit connected to the switching unit and configured to match impedance of a path through which an electrical signal is transmitted to one of the sensors of the sensor board to a reference value, [0131], and calibration is configured to be performed while the calibration board is connected to the second connector, [0125]. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTINE T MUI whose telephone number is (571)270-3243. The examiner can normally be reached M-Th 5:30 -15:30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, LYLE ALEXANDER can be reached at (571) 272-1254. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. CTM /CHRISTINE T MUI/Primary Examiner, Art Unit 1797
Read full office action

Prosecution Timeline

Dec 27, 2023
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12789183
LINEAR MICROFLUIDIC DEVICE
3y 4m to grant Granted Nov 10, 2026
Patent 12773693
MICROFLUIDIC DEVICE CHAMBER PILLARS
2y 10m to grant Granted Oct 27, 2026
Patent 12760327
DEVICE FOR CELL TREATMENT
3y 8m to grant Granted Oct 13, 2026
Patent 12761230
METHODS AND SYSTEMS FOR DIAGNOSING DISEASES
3y 3m to grant Granted Oct 13, 2026
Patent 12752269
Large Scale Microdroplet Generation Apparatus And Methods Of Manufacturing Thereof
5y 2m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
78%
Grant Probability
98%
With Interview (+19.7%)
2y 8m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1399 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month